1) release rate
释放度
1.
Preparation and release rate determination of Emedastine Difumarate Sustained-release Tablets;
富马酸依美斯汀缓释片的制备及释放度的测定
2.
Effect of formula of flurbiprofen sustained-release tablets on its release rate;
氟比诺芬缓释片的处方工艺对释放度的影响
3.
In vitro antibacterial activities and in vivo release rate of the ornidazole slow-release membranes;
奥硝唑缓释膜体外抑菌性及体内释放度的研究
2) dissolution
[英][,dɪsə'lu:ʃn] [美]['dɪsə'luʃən]
释放度
1.
Preparation and Dissolution of Gliclazide Sustained Release Tablets in Vitro;
格列齐特缓释片的研制及体外释放度考察
2.
Investigation on the dissolution of Nimodipine sustained release capsules;
市售尼莫地平缓释胶囊的释放度考察
3.
Studies on dissolution of fluorouracil sustained-release implant in vitro and relation with drug concentration in vivo;
植入用缓释氟尿嘧啶释放度检查及体内外相关性研究
3) Release
[英][rɪ'li:s] [美][rɪ'lis]
释放度
1.
Comparison of release characteristics between two mizolastine sustained release tablets in vitro;
2种咪唑斯汀缓释片的体外释放度比较
2.
Study on the External Release Characteristics of Tramadol Hydrochloride Sustained-Release Tablets;
盐酸曲马多缓释片的体外释放度研究
3.
Preparation and Release of Compound Captopril Sustained-release Double Layer Tablets;
复方卡托普利缓释双层片的研制及释放度影响因素
4) drug release
释放度
1.
Preparation of ribavrin sustained release tablets and its drug release;
利巴韦林缓释片的制备及其释放度测定
2.
Study on the preparation of trapidil sustained-release tablets and the in vitro drug release;
曲匹地尔缓释片的制备与体外释放度测定
3.
Investigation on the preparation and drug release in vitro of the captopril osmotic pump-controlled release tablets;
卡托普利渗透泵控释片的制备及体外释放度考察
5) dissolution rate
释放度
1.
Determination of dissolution rate of levodropropizine sustained-release tablets;
左羟丙哌嗪缓释片体外释放度测定
2.
The comparison of dissolution rates of diclofenac sodium slow-released capsules;
双氯芬酸钠缓释胶囊体外释放度考察
3.
RESULTS The dissolution rate is decreased as hydroxypropylmethylcellulose(HPMC) increasing;Lactose and dextrin is good for preparing nimodipine sustained-release tablets;CONCLUSION No great difference in dissolution behavior is observed between market nimodipine sustained-release tablets and trial-products.
方法通过比较体外释放度筛选处方。
6) release depth
释放深度
1.
The beginning and release depth of mudstone overpressure in different evolution stages and its implication;
泥岩超压不同演化阶段开始及释放深度规律及其研究意义
2.
This method was utilized to study the factors that influence the release depth and times of overpressure of mudstone by theoretical calculating;we found overpressure of mudstone is the periodical product in the compacting process which can only form when t.
在泥岩超压形成机制和条件研究的基础上,通过泥岩超压形成与演化规律的研究,建立了一套泥岩超压释放深度和次数的研究方法,利用此方法通过理论计算对泥岩超压释放深度和次数的主要影响因素进行了研究,得到泥岩超压是其压实过程中的阶段产物,只有当压实成岩达到一定程度后方可形成,当超过泥岩破裂极限后便发生破裂超压释放,超压降低以致消失。
补充资料：促甲状腺素释放激素、促甲释放素
分子式：
CAS号：
性质：又称促甲状腺素释放激素、促甲释放素。为简单的三肽。易溶于无水甲醇，略溶于氯仿，不溶于吡啶。为下丘脑分泌的多肽激素。促进垂体生成促甲状腺素，同时还能刺激垂体释放泌乳素。可影响细胞钙库，增加Ca2+浓度而发挥作用；且有抗内毒素性休克作用。用于诊断甲状腺功能，判定甲状腺功能亢进复发趋势。也可治疗甲状腺机能减退和甲状腺癌患者。制剂为注射剂。
CAS号：
性质：又称促甲状腺素释放激素、促甲释放素。为简单的三肽。易溶于无水甲醇，略溶于氯仿，不溶于吡啶。为下丘脑分泌的多肽激素。促进垂体生成促甲状腺素，同时还能刺激垂体释放泌乳素。可影响细胞钙库，增加Ca2+浓度而发挥作用；且有抗内毒素性休克作用。用于诊断甲状腺功能，判定甲状腺功能亢进复发趋势。也可治疗甲状腺机能减退和甲状腺癌患者。制剂为注射剂。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条